1.
Pop MS, Stransky N, Garvie CW, et al. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Mol Cancer Ther. 2014;13(6):1492-502. doi:10.1158/1535-7163.MCT-13-0689.
1.
Pomerantz MM, Li F, Takeda DY, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47(11):1346-51. doi:10.1038/ng.3419.
1.
Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321-30. doi:10.1016/j.ccr.2006.09.005.
1.
Li Q, Stram A, Chen C, et al. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum Mol Genet. 2014;23(19):5294-302. doi:10.1093/hmg/ddu228.
1.
Mancuso N, Rohland N, Rand KA, et al. The contribution of rare variation to prostate cancer heritability. Nat Genet. 2016;48(1):30-5. doi:10.1038/ng.3446.
1.
Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815-25. doi:10.1158/0008-5472.CAN-05-4000.
1.
Theurillat J-PP, Udeshi ND, Errington WJ, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346(6205):85-9. doi:10.1126/science.1250255.
1.
Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002;1(2):203-9.
1.
Febbo PG, Löwenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol. 2005;173(5):1772-7. doi:10.1097/01.ju.0000155845.44729.ba.
1.
Zaitlen N, Pasaniuc B, Sankararaman S, et al. Leveraging population admixture to characterize the heritability of complex traits. Nat Genet. 2014;46(12):1356-62. doi:10.1038/ng.3139.